Physician profile
Michael B Herlich
NPI 1891748109
$1,715.61
in general payments reported to CMS, 2019-2025
15 companies · $148 in 2025
The $148 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $429 · 2020: $375 · 2021: $261 · 2023: $241 · 2024: $262 · 2025: $148.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $650.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $650.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Impulse Dynamics (USA) INC. | $635.28 | 2023-2025 | Optimizer, Optimizer |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $320.58 | 2019-2021 | |
| Amgen INC. | $166.17 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $115.10 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $83.23 | 2019-2020 | |
| Amarin Pharma, INC. | $77.44 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $73.47 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $69.66 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $52.37 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $29.34 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $28.24 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $26.73 | 2020-2021 | |
| Regeneron Healthcare Solutions, INC. | $13.24 | 2019 | |
| W. L. Gore & Associates, INC. | $12.81 | 2020 | |
| Pfizer INC. | $11.95 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Herlich listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.